Search
AZD-6482
go.drugbank.com/drugs/DB14980InvestigationalAZD-6482 is under investigation in clinical trial NCT00688714 (Study to Investigate Safety and Tolerability of a Single Dose of AZD6482).
Cobalt Co-60
go.drugbank.com/drugs/DB15374ExperimentalCobalt Co-60 is under investigation in clinical trial NCT02891083 (Adjuvant Therapies or Surgery Alone for High Risk pN0 Esophageal Cancer).
Sepantronium
go.drugbank.com/drugs/DB17062InvestigationalSepantronium is a compound that suppresses survivin expression in a dose and time-dependent manner, and causes broad-range apoptosis.[A253167]
Olpasiran
go.drugbank.com/drugs/DB19001InvestigationalOlpasiran is under investigation in clinical trial NCT05581303 (Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (Ocean(a)) - Outcomes Trial).
Streptodornase
go.drugbank.com/drugs/DB19273InvestigationalStreptodornase is under investigation in clinical trial NCT04252963 (Clinical Trial to Assess the Efficacy and Safety of MUCOLASE Tablet(streptokinase • Streptodornase)).
Procizumab
go.drugbank.com/drugs/DB23041InvestigationalProcizumab is under investigation in clinical trial NCT06331884 (Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics/-Dynamics of AK1967 (Procizumab)).
NBQ72S
go.drugbank.com/drugs/DB26052InvestigationalNBQ72S is under investigation in clinical trial NCT06810804 (A Phase IIa Study to Evaluate NBQ72S).
Coenzyme A
go.drugbank.com/drugs/DB01992InvestigationalNutraceuticalCoenzyme A (CoA, CoASH, or HSCoA) is a coenzyme, well known for it's role in the synthesis and oxidation of fatty acids, and the oxidation of pyruvate in the citric acid cycle.
FINLAY-FR-1
go.drugbank.com/drugs/DB16524Experimental, of the prophylactic FINLAY-FR-1 anti-SARS-CoV-2 Vaccine Candidate in a two-doses schedule. … It is currently being tested in the clinical trial RPCEC00000332 (Phase I / II, randomized, controlled, adaptive, double-blind and multicenter study to evaluate the safety, reactogenicity and immunogenicity
Gemcabene
go.drugbank.com/drugs/DB05123InvestigationalGemcabene is a new drug that lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C).